MedAssets, Inc. (NASDAQ: MDAS), Humana (NYSE: HUM), Synchronoss Technologies, Inc. (NASDAQ: SNCR), Digital Realty Trust, Inc. (NYSE: DLR), Frontline Ltd. (NYSE: FRO), Ariad Pharmaceutical (NASDAQ: ARIA), Allegiant Travel (NASDAQ: ALGT), Capital Product Partners L.P. (NASDAQ: CPLP) and Gevo, Inc. (NASDAQ: GEVO) price targets adjusted by analysts.
MedAssets, Inc. (MDAS) had its price target lowered by UBS AG (NYSE:UBS) from $15.50 to $13.00. The have a “Neutral” rating on the company.
Humana (NYSE: HUM) had its price target raised by Barclays Capital from $85.00 to $90.00. They have an “Equal Weight” rating on the company.
Synchronoss Technologies, Inc. (SNCR) had its price target raised by Stifel Nicolaus from $38.00 to $44.00. They have a “Buy” rating on the company.
Digital Realty Trust, Inc. (DLR) had its price target lowered by Barclays Capital from $70.00 to $67.00. They have an “Overweight” rating on the company.
Frontline Ltd. (FRO) had its price target lowered by Deutsche Bank (NYSE:DB) from $22.00 to $16.00. They have a “Buy” rating on the company.
Ariad Pharmaceutical (ARIA) had its price target raised by Brean Murray from $11.00 to $15.00. They have a “Buy” rating on the company.
Allegiant Travel (ALGT) had its price target cut by Barclays Capital from $65.00 to $61.00. They have an “Overweight” rating on the company.
Capital Product Partners L.P. (CPLP) had its price target lowered by Deutsche Bank from $9.00 to $8.00. They have a “Hold” rating on the company.
Gevo, Inc. (GEVO) had its price target boosted by UBS AG from $21.00 to $23.00. They have a “Buy” rating on the company.
Showing posts with label ARIAD Pharmaceuticals. Show all posts
Showing posts with label ARIAD Pharmaceuticals. Show all posts
Wednesday, August 3, 2011
Thursday, January 20, 2011
ARIAD Pharma (Nasdaq:ARIA) Getting Closer to Ridaforolimus Approval
ARIAD Pharma's (Nasdaq:ARIA) cancer drug ridaforolimus has enjoyed successful results from studies, and has an excellent chance of being approved.
Canaccord says, "Patients taking ridaforolimus, an oral cancer drug under development by Ariad Pharmaceuticals, had better survival rates compared to those taking a placebo, according to the results of a recent study. Ridaforolimus reduced the risk of progression in a type of cancerous tumours known as sarcomas by as much as 28%, said Ariad, and patients lived about three weeks longer without their cancer worsening. Patients exhibited few side-effects, the most common being dry mouth sores, fatigue, diarrhea and platelet disorders. 'Overall we’re certainly enthusiastic about it,' said Ariad CEO Harvey Berger. The company plans to seek U.S. clearance for the drug this year alongside partner Merck (NYSE:MRK). If approved, ridaforolimus could generate the partnership $365 million by 2015, noted one analyst at Cowen & Co. 'Metastatic sarcoma is a fatal disease for which there are very few active therapies available today, and thus the unmet medical need is high,' the analyst explained. 'The data are solid, and likely to get ridaforolimus on the market.' About 12,000 U.S. patients are diagnosed with sarcomas each year."
ARIAD Pharma (Nasdaq:ARIA) closed Wednesday at $6.27, dropping $0.76, or 10.87 percent.
Canaccord says, "Patients taking ridaforolimus, an oral cancer drug under development by Ariad Pharmaceuticals, had better survival rates compared to those taking a placebo, according to the results of a recent study. Ridaforolimus reduced the risk of progression in a type of cancerous tumours known as sarcomas by as much as 28%, said Ariad, and patients lived about three weeks longer without their cancer worsening. Patients exhibited few side-effects, the most common being dry mouth sores, fatigue, diarrhea and platelet disorders. 'Overall we’re certainly enthusiastic about it,' said Ariad CEO Harvey Berger. The company plans to seek U.S. clearance for the drug this year alongside partner Merck (NYSE:MRK). If approved, ridaforolimus could generate the partnership $365 million by 2015, noted one analyst at Cowen & Co. 'Metastatic sarcoma is a fatal disease for which there are very few active therapies available today, and thus the unmet medical need is high,' the analyst explained. 'The data are solid, and likely to get ridaforolimus on the market.' About 12,000 U.S. patients are diagnosed with sarcomas each year."
ARIAD Pharma (Nasdaq:ARIA) closed Wednesday at $6.27, dropping $0.76, or 10.87 percent.
Wednesday, January 19, 2011
ARIAD Pharmaceuticals (NASDAQ:ARIA) and 3-Week PFS Benefit
ARIAD Pharmaceuticals (NASDAQ:ARIA) could strengthen from a 3-week PFS benefit, which should be outlined thoroughly at ASCO in June.
Barclays says, "With focus on clinical relevance of a 3-week PFS benefit we believe that investigator assessed PFS of -8 weeks is more likely to reflect clinically relevant progression than central radiographic review and to track with both cancer related symptom progression and overall survival trends. We expect detail of data at ASCO in June to be better than the headline and would buyers on today's muted reaction.
With focus on clinical relevance of a 3.1 week PFS benefit we would note the approval of Tarceva for NSCLC maintenance therapy on -1 month benefit and on -2 week benefit in pancreatic CA. We expect significant focus on secondary endpoints of overall survival (OS) and cancer related symptoms and believe that clinician rated progression is likely more indicative of overall patient benefit on these metrics than that from centralized radiologists. Based on Sarcoma natural history we expect >50% of deaths to occur before ASCO and for sufficient detail to support regulatory filing in 2H11."
Barclays maintains an "Overweight" rating on ARIAD Pharmaceuticals (ARIA), which was trading at $6.47, down $0.57, or 8.03 percent, as of 1:44 PM EST. Barclays has a price target on ARIAD of $9.
Barclays says, "With focus on clinical relevance of a 3-week PFS benefit we believe that investigator assessed PFS of -8 weeks is more likely to reflect clinically relevant progression than central radiographic review and to track with both cancer related symptom progression and overall survival trends. We expect detail of data at ASCO in June to be better than the headline and would buyers on today's muted reaction.
With focus on clinical relevance of a 3.1 week PFS benefit we would note the approval of Tarceva for NSCLC maintenance therapy on -1 month benefit and on -2 week benefit in pancreatic CA. We expect significant focus on secondary endpoints of overall survival (OS) and cancer related symptoms and believe that clinician rated progression is likely more indicative of overall patient benefit on these metrics than that from centralized radiologists. Based on Sarcoma natural history we expect >50% of deaths to occur before ASCO and for sufficient detail to support regulatory filing in 2H11."
Barclays maintains an "Overweight" rating on ARIAD Pharmaceuticals (ARIA), which was trading at $6.47, down $0.57, or 8.03 percent, as of 1:44 PM EST. Barclays has a price target on ARIAD of $9.
Tuesday, January 18, 2011
Ariad (Nasdaq:ARIA) Shares Explode Upward on Positive Phase III
Based on positive results from it successful Phase III trial for its cander drug "Ridaforolimus," shares of Ariad (Nasdaq:ARIA) has soared over 30 percent in mid-day trading.
Ridaforolimus is being developed to treat cancerous tumor of bone of soft tissue.
Ariad's partner in developing the new drug is Merck & Co. (NYSE:MRK)
Ariad was trading at $6.88, gaining $1.64, or 31.14 percent, a of 1:31 PM EST.
Ridaforolimus is being developed to treat cancerous tumor of bone of soft tissue.
Ariad's partner in developing the new drug is Merck & Co. (NYSE:MRK)
Ariad was trading at $6.88, gaining $1.64, or 31.14 percent, a of 1:31 PM EST.
Thursday, January 6, 2011
ARIAD (NASDAQ:ARIA) Partner Merck (NYSE:MRK) Reporting Ridaforolimus Data in 1Q
With an approximate 60 percent chance of success for ridaforolimus, ARIAD Pharmaceuticals (NASDAQ:ARIA) looks good going forward, as partner Merck (NYSE:MRK) is poised to post their report in the first quarter, according to Jefferies (NYSE:JEF).
If it is successful the company is predicting a - $3/sh upside to current valuation and they're doing that by assigning a 90% probability to their - $500M WW peak sales estimate in sarcoma in 2020 and 70% probability to their - $650M in WW peak sales in endometrial cancer in 2020, with 20% royalty on total sales to ARIA, along with $65 million in potential regulatory milestones from Merck.
ARIAD Pharmaceuticals closed Wednesday at $5.23, up $0.13, or 2.55 percent. Jefferies raised their price target on them from $6 to $8.
If it is successful the company is predicting a - $3/sh upside to current valuation and they're doing that by assigning a 90% probability to their - $500M WW peak sales estimate in sarcoma in 2020 and 70% probability to their - $650M in WW peak sales in endometrial cancer in 2020, with 20% royalty on total sales to ARIA, along with $65 million in potential regulatory milestones from Merck.
ARIAD Pharmaceuticals closed Wednesday at $5.23, up $0.13, or 2.55 percent. Jefferies raised their price target on them from $6 to $8.
Subscribe to:
Posts (Atom)